{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:47:31Z","timestamp":1787600851777,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA05557-02"],"award-info":[{"award-number":["DA05557-02"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      \u2018Kava,\u2019 or \u2018kava kava,\u2019 (\n                      <jats:italic>Piper methysticum<\/jats:italic>\n                      ) is a psychoactive plant indigenous to the Pacific Islands. Historical consumption is reported to provide anxiolytic and sedating effects. In regions where kava is native, it has been used in religious and cultural practices, as well as for medicinal purposes. The mechanisms by which kavalactones \u2013 the best studied psychoactive constituent of kava \u2013 may mediate pharmacological effects include enhancing the GABA\n                      <jats:sub>A<\/jats:sub>\n                      receptor, blocking of sodium and calcium channels, blocking reuptake of norepinephrine dopamine, and inhibiting MAO-B. In the United States, products containing kava have proliferated in recent years alongside the rise of ethnobotanical tea bars serving kava preparations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Between December\u2013July 2024, an anonymous online survey on legal psychoactive products was conducted using convenience sampling. Eligible individuals had to be\n                      <jats:italic>\u2265<\/jats:italic>\n                      \u200918 years old and endorse lifetime use of kratom, kava, tianeptine, and\/or akuamma seed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 368 participants, almost half (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009180, 48.9%) had used kava during their lifetime. Those who reported lifetime use of kava were younger on average (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), more racially diverse (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041), and had a higher proportion of being employed or in school (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012) than those where did not use kava in their lifetime. Kava was purchased online (40.6%) or in ethnobotanical tea bars (31.7%). Many reported infrequent consumption (average\u2009=\u20094.4 months\/year and 9.1 days\/30 days). Lifetime use of alcohol, kratom, and cannabis was common. Approximately one-third of participants had consumed kava more than 100 times, with commonly reported perceived effects from kava experienced in the minutes and hours after consumption included reduced general anxiety (33.7%), improved mood (32.9%), reduced social anxiety (25.5%), and sedation (23.4%). Most respondents had favorable conceptualizations of kava, with only 11.7% characterizing that kava alone as habit-forming. Many (51.7%) conceptualized kava as an alcohol replacement with 18.3% and 16.7% using kava as a short- and\/or long-term substitute for alcohol, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Kava use practices are diverse, though perceived kava effects appear mostly mild. The proliferation and diversification of kava products pre-mixed with other psychoactive botanicals requires study as the benefit-risk profile may change. Clinicians should be aware of kava use for harm-reduction and other purposes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13011-026-00728-3","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:15:42Z","timestamp":1777994142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kava (Piper methysticum) consumption patterns and conceptualizations: results from an online survey"],"prefix":"10.1186","volume":"21","author":[{"given":"Katherine","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cianna","family":"Piercey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollis C.","family":"Karoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"728_CR1","doi-asserted-by":"publisher","first-page":"113582","DOI":"10.1016\/j.jep.2020.113582","volume":"268","author":"M Thomsen","year":"2021","unstructured":"Thomsen M, Schmidt M. Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop. J Ethnopharmacol. 2021;268:113582. https:\/\/doi.org\/10.1016\/j.jep.2020.113582.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"728_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0190-9622(94)70142-3","volume":"31","author":"SA Norton","year":"1994","unstructured":"Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol. 1994;31(1):89\u201397. https:\/\/doi.org\/10.1016\/S0190-9622(94)70142-3.","journal-title":"J Am Acad Dermatol"},{"key":"728_CR3","doi-asserted-by":"publisher","unstructured":"Martin AC, Johnston E, Xing C, Hegeman AD. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). Polyak SJ, editor. PLoS ONE. 2014;9(11):e111572. https:\/\/doi.org\/10.1371\/journal.pone.0111572.","DOI":"10.1371\/journal.pone.0111572"},{"key":"728_CR4","unstructured":"Lebot V, Merlin M, Lindstrom L, Kava. The Pacific Elixir: the definitive guide to its ethnobotany, history, and chemistry. Bear & Co; 1997."},{"issue":"1","key":"728_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13063-015-0986-5","volume":"16","author":"KM Savage","year":"2015","unstructured":"Savage KM, Stough CK, Byrne GJ, Scholey A, Bousman C, Murphy J, et al. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials. 2015;16(1):493. https:\/\/doi.org\/10.1186\/s13063-015-0986-5.","journal-title":"Trials"},{"issue":"1","key":"728_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1353\/cul.0.0029","volume":"71","author":"YN Singh","year":"2009","unstructured":"Singh YN, Kava. An old drug in a new world. Cult Crit. 2009;71(1):107\u201328. https:\/\/doi.org\/10.1353\/cul.0.0029.","journal-title":"Cult Crit"},{"issue":"5","key":"728_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0305-1978(01)00093-X","volume":"30","author":"P Sim\u00e9oni","year":"2002","unstructured":"Sim\u00e9oni P, Lebot V. Identification of factors determining kavalactone content and chemotype in Kava (Piper methysticum Forst. f). Biochem Syst Ecol. 2002;30(5):413\u201324. https:\/\/doi.org\/10.1016\/S0305-1978(01)00093-X.","journal-title":"Biochem Syst Ecol"},{"issue":"1","key":"728_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9673(98)00699-2","volume":"825","author":"Y Shao","year":"1998","unstructured":"Shao Y, He K, Zheng B, Zheng Q. Reversed-phase high-performance liquid chromatographic method for quantitative analysis of the six major kavalactones in Piper methysticum. J Chromatogr A. 1998;825(1):1\u20138. https:\/\/doi.org\/10.1016\/S0021-9673(98)00699-2.","journal-title":"J Chromatogr A"},{"issue":"1","key":"728_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/00048674.2010.522554","volume":"45","author":"J Sarris","year":"2011","unstructured":"Sarris J, LaPorte E, Schweitzer I, Kava. A comprehensive review of efficacy, safety and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27\u201335. https:\/\/doi.org\/10.3109\/00048674.2010.522554.","journal-title":"Aust N Z J Psychiatry"},{"key":"728_CR10","doi-asserted-by":"publisher","unstructured":"Kapalka GM. Anxiety disorders. In: Nutritional and Herbal Therapies for Children and Adolescents [Internet]. Elsevier; 2010 [cited 2025 Jun 27]. pp. 219\u201358. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B978012374927700008Xhttps:\/\/doi.org\/10.1016\/B978-0-12-374927-7.00008-X","DOI":"10.1016\/B978-0-12-374927-7.00008-X"},{"key":"728_CR11","doi-asserted-by":"publisher","unstructured":"Chua HC, Christensen ETH, Hoestgaard-Jensen K, Hartiadi LY, Ramzan I, Jensen AA, et al. Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: functional characteristics and molecular mechanism. Barnes S, editor. PLoS ONE. 2016;11(6):e0157700. https:\/\/doi.org\/10.1371\/journal.pone.0157700.","DOI":"10.1371\/journal.pone.0157700"},{"issue":"2","key":"728_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1600-0773.1992.tb00530.x","volume":"71","author":"LP Davies","year":"1992","unstructured":"Davies LP, Drew CA, Duffield P, Johnston GAR, Jamieson DD. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol. 1992;71(2):120\u20136. https:\/\/doi.org\/10.1111\/j.1600-0773.1992.tb00530.x.","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"728_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s002130100686","volume":"155","author":"KK Smith","year":"2001","unstructured":"Smith KK, Dharmaratne HRW, Feltenstein MW, Broom SL, Roach JT, Nanayakkara NPD, et al. Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm. Psychopharmacol. 2001;155(1):86\u201390. https:\/\/doi.org\/10.1007\/s002130100686.","journal-title":"Psychopharmacology"},{"issue":"1","key":"728_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/00952990.2022.2140292","volume":"49","author":"S Pont-Fernandez","year":"2023","unstructured":"Pont-Fernandez S, Kheyfets M, Rogers JM, Smith KE, Epstein DH. Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects. Am J Drug Alcohol Abuse. 2023;49(1):85\u201396. https:\/\/doi.org\/10.1080\/00952990.2022.2140292.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"728_CR15","doi-asserted-by":"publisher","unstructured":"Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Common Mental Disorders Group, editor. Cochrane Database Syst Rev. 2003 Jan;20. https:\/\/doi.org\/10.1002\/14651858.CD003383.","DOI":"10.1002\/14651858.CD003383"},{"issue":"01","key":"728_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2007-979474","volume":"30","author":"HP Volz","year":"1997","unstructured":"Volz HP, Kieser M. Kava-kava extract. WS 1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997;30(01):1\u20135. https:\/\/doi.org\/10.1055\/s-2007-979474.","journal-title":"Pharmacopsychiatry"},{"key":"728_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ctcp.2018.09.003","volume":"33","author":"K Smith","year":"2018","unstructured":"Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: a systematic review and analysis of randomized clinical trials. Complement Ther Clin Pract. 2018;33:107\u201317. https:\/\/doi.org\/10.1016\/j.ctcp.2018.09.003.","journal-title":"Complement Ther Clin Pract"},{"key":"728_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phymed.2018.08.011","volume":"56","author":"MW Becker","year":"2019","unstructured":"Becker MW, Louren\u00e7one EMS, De Mello AF, Branco A, Filho EMR, Blatt CR, et al. Liver transplantation and the use of KAVA: Case report. Phytomedicine. 2019;56:21\u20136. https:\/\/doi.org\/10.1016\/j.phymed.2018.08.011.","journal-title":"Phytomedicine"},{"issue":"9","key":"728_CR19","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/j.1478-3231.2010.02308.x","volume":"30","author":"R Teschke","year":"2010","unstructured":"Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations: Kava hepatotoxicity. Liver Int. 2010;30(9):1270\u20139. https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02308.x.","journal-title":"Liver Int"},{"issue":"10","key":"728_CR20","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1021\/tx5003194","volume":"27","author":"SC Narayanapillai","year":"2014","unstructured":"Narayanapillai SC, Leitzman P, O\u2019Sullivan MG, Xing C. Flavokawains A and B in kava, Not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL\/6 Mice. Chem Res Toxicol. 2014;27(10):1871\u20136. https:\/\/doi.org\/10.1021\/tx5003194.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"728_CR21","doi-asserted-by":"publisher","first-page":"e2353401","DOI":"10.1001\/jamanetworkopen.2023.53401","volume":"7","author":"KE Smith","year":"2024","unstructured":"Smith KE, Panlilio LV, Feldman JD, Grundmann O, Dunn KE, McCurdy CR, et al. Ecological momentary assessment of self-reported kratom use, effects, and motivations among us adults. JAMA Netw Open. 2024;7(1):e2353401. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53401.","journal-title":"JAMA Netw Open"},{"key":"728_CR22","doi-asserted-by":"publisher","unstructured":"Gnanasegaram SA, Sexton L, Stanciu CN. Kratom consumption \u2013 the tales of three patients. J Psychoact Drugs. 2024;1\u20134. https:\/\/doi.org\/10.1080\/02791072.2024.2424278.","DOI":"10.1080\/02791072.2024.2424278"},{"key":"728_CR23","doi-asserted-by":"publisher","unstructured":"Bleifuss W, Boley S, Bardwell J, Goebel C, Wilkinson J. Severe kava withdrawal managed with phenobarbital. Am J Emerg Med. 2025;S0735675725003973. https:\/\/doi.org\/10.1016\/j.ajem.2025.06.016.","DOI":"10.1016\/j.ajem.2025.06.016"},{"key":"728_CR24","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.dadr.2025.100394","volume":"17","author":"K Hill","year":"2025","unstructured":"Hill K, Boyer EW, Smith KE. Clinically characterizing adults who use kava or kratom: Substance use disorder assessment challenges for increasingly popular botanical products. Drug Alcohol Depend Rep. 2025;17:100394. https:\/\/doi.org\/10.1016\/j.dadr.2025.100394.","journal-title":"Drug Alcohol Depend Rep"},{"key":"728_CR25","unstructured":"Whole Foods Market [Internet]. [cited 2025 Aug 10]. Kava Kava Root Extract, 1 FZ at Whole Foods Market. Available from: https:\/\/www.wholefoodsmarket.com\/product\/kava-kava-root-extract, 1 fz-b00f1j8byw."},{"key":"728_CR26","unstructured":"Kava | Buy Premium Kava - Relax & Unwind Naturally | Pure Leaf Kratom [Internet]. [cited 2025 Aug 10]. Available from: https:\/\/pureleafkratom.com\/collections\/kava"},{"key":"728_CR27","doi-asserted-by":"publisher","unstructured":"Dufour J, Lin XL, Wang J, Baisley J, Atif A, Berthold EC, et al. The safety of multiple-dose liquid blend containing kava and kratom in healthy adults. Cureus. 2024 Dec 13. https:\/\/doi.org\/10.7759\/cureus.75654","DOI":"10.7759\/cureus.75654"},{"key":"728_CR28","unstructured":"DFI. Review of the published literature pertaining to the safety of Kava for use in conventional foods [Internet]. FDA. 2020. Report No. Available from: https:\/\/www.fda.gov\/media\/169556\/download"},{"key":"728_CR29","doi-asserted-by":"publisher","unstructured":"Piercey CJ, Bunch J, Cameron J, Ahern R, Packwood I, Bruning C, et al. Kratom use among ethnobotanical tea bar patrons in Colorado: Subjective drug effects, adverse reactions, and perceived benefits of use. Drug Alcohol Depend Rep. 2025;100361. https:\/\/doi.org\/10.1016\/j.dadr.2025.100361.","DOI":"10.1016\/j.dadr.2025.100361"},{"key":"728_CR30","doi-asserted-by":"publisher","unstructured":"Piercey CJ, Cameron J, Ahern W, Packwood B, Bruning C, Henry D, et al. Characteristics of adverse reactions to kratom and implementation of harm reduction strategies in a sample of ethnobotanical tea bar Patrons in Colorado [Internet]. 2025 [cited 2025 Aug 10]. Available from: https:\/\/osf.io\/6qjm3; https:\/\/doi.org\/10.31234\/osf.io\/6qjm3","DOI":"10.31234\/osf.io\/6qjm3"},{"key":"728_CR31","unstructured":"Council for Responsible Nutrition. CRN list of dietary ingredients. Grandfathered under DSHEA [Internet]. 1998 Sep. p. 16. Report No. Available from: https:\/\/www.crnusa.org\/sites\/default\/files\/RAC%20attachments\/CRNGrandfatherlist.pdf."},{"key":"728_CR32","unstructured":"KAVA [Internet]. Drug enforcement administration, diversion control division, drug & chemical evaluation section.\u00a0 2025 Mar. p. 1. Report No. Available from: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/kava.pdf"},{"key":"728_CR33","unstructured":"McGhee H. Hepatic toxicity possibly associated with Kava-containing products\u2013United States, Germany, and Switzerland, 1999\u20132002 [Internet]. CDC MMWR; 2002 Nov. Report No. Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5147a1.htm."},{"key":"728_CR34","unstructured":"Advisory FDAC. Kava-containing dietary supplements may be associated with severe liver injury [Internet]. U.S. Department of Health and Human Services; 2002 Mar. Report No. Available from: https:\/\/wayback.archive-it.org\/7993\/20170722144010\/https:\/www.fda.gov\/Food\/RecallsOutbreaksEmergencies\/SafetyAlertsAdvisories\/ucm085482.htm"},{"issue":"2","key":"728_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/00952990.2024.2414319","volume":"51","author":"K Hill","year":"2025","unstructured":"Hill K, Rogers JM, Grundmann O, Epstein DH, Smith KE. At least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use. Am J Drug Alcohol Abuse. 2025;51(2):191\u2013203. https:\/\/doi.org\/10.1080\/00952990.2024.2414319.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"728_CR36","unstructured":"Dobis E, Sanders A. Rural-urban commuting area codes - Documentation. 2025."},{"key":"728_CR37","doi-asserted-by":"publisher","first-page":"1174139","DOI":"10.3389\/fphar.2023.1174139","volume":"14","author":"KE Smith","year":"2023","unstructured":"Smith KE, Feldman JD, Dunn KE, McCurdy CR, Weiss ST, Grundmann O, et al. Examining the paradoxical effects of kratom: a narrative inquiry. Front Pharmacol. 2023;14:1174139. https:\/\/doi.org\/10.3389\/fphar.2023.1174139.","journal-title":"Front Pharmacol"},{"issue":"4","key":"728_CR38","first-page":"364","volume":"56","author":"WH Newell","year":"1947","unstructured":"Newell WH. The kava ceremony in Tonga. J Polyn Soc. 1947;56(4):364\u2013417.","journal-title":"J Polyn Soc"},{"issue":"3","key":"728_CR39","first-page":"9","volume":"4","author":"LD Holmes","year":"1967","unstructured":"Holmes LD. Piper methysticium (kava). The function of kava in modern Samoan culture. Psychopharmacol Bull. 1967;4(3):9. PubMed PMID: 5615555.","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"728_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2307\/3773584","volume":"25","author":"JW Turner","year":"1986","unstructured":"Turner JW. The water of life: Kava ritual and the logic of sacrifice. Ethnology. 1986;25(3):203. https:\/\/doi.org\/10.2307\/3773584.","journal-title":"Ethnology"},{"issue":"1","key":"728_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12110-014-9191-6","volume":"25","author":"JH Shaver","year":"2014","unstructured":"Shaver JH, Sosis R. How does male ritual behavior vary across the lifespan? An examination of Fijian Kava ceremonies. Hum Nat. 2014;25(1):136\u201360. https:\/\/doi.org\/10.1007\/s12110-014-9191-6.","journal-title":"Hum Nat"},{"issue":"2","key":"728_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.15288\/qjsa.1967.28.328","volume":"28","author":"EM Lemert","year":"1967","unstructured":"Lemert EM. Secular use of kava in Tonga. Q J Stud Alcohol. 1967;28(2):328\u201341. https:\/\/doi.org\/10.15288\/qjsa.1967.28.328.","journal-title":"Q J Stud Alcohol"},{"issue":"1","key":"728_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12954-015-0080-z","volume":"12","author":"R Power","year":"2015","unstructured":"Power R, Schmich L, Nosa V. A response for substance and harm reduction in Pacific Island countries and territories. Harm Reduct J. 2015;12(1):48. https:\/\/doi.org\/10.1186\/s12954-015-0080-z.","journal-title":"Harm Reduct J"},{"key":"728_CR44","unstructured":"Faleolo MM, Ravulo J, Getting on the K.A.D. The impacts of kava, alcohol and other drug consumption across Pacific communities. In: Pacific Social Work. Routledge; 2019."},{"issue":"2","key":"728_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/713659319","volume":"19","author":"D Mcdonald","year":"2000","unstructured":"Mcdonald D, Jowitt A. Kava in the Pacific Islands: a contemporary drug of abuse? Drug Alcohol Rev. 2000;19(2):217\u201327. https:\/\/doi.org\/10.1080\/713659319.","journal-title":"Drug Alcohol Rev"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-026-00728-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00728-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00728-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:45:26Z","timestamp":1782783926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13011-026-00728-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1186\/s13011-026-00728-3","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was The Johns Hopkins University School of Medicine Institutional Review Board determined this did not qualify as human subjects\u2019 research due to the anonymous study design. Individuals could voluntarily choose to participate in the anonymous survey or not after reading about the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Within the past three years, KES has served as a paid scientific consultant to the International Plant and Herbal Alliance; Todd, Brown, and Frost; Porto Law Firm; and Amin, Wasserman, Gurnani and has served as expert witness in legal cases involving kratom. None of these relationships are related to kava. Within the past year, KH has served as an expert witness in a legal case involving kratom and 7-OH; the case was not related to kava.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}